Vivimed sells part of specialty chemicals biz to Clariant for Rs 380 crore

Company to use funds to reduce debt

Image via Shutterstock
<a href="http://www.shutterstock.com/pic-228848833/stock-photo-pills-drug.html" target="_blank">Image</a> via Shutterstock
Dasarath Reddy Hyderabad
Last Updated : Sep 30 2015 | 1:00 PM IST

Hyderabad-based Vivimed Labs today said it has signed a definitive agreement for the transfer and sale of a portion of its specialty chemicals product portfolio along with associated trademarks and assets to Clariant Chemicals (India) Limited, a subsidiary of Clariant AG of Switzerland.

The deal value is Rs 380 crore.

The part of the specialty chemicals business being divested to Clariant accounted for about 10% of the consolidated revenue from operations in the last financial year, according to Vivimed.

The consolidated revenues stood at Rs 1,386 crore in the financial year 2014-15.

"This transaction will help us significantly improve financial flexibility for future growth. We are confident that this transaction, once completed, will position Vivimed optimally to the next level of growth across its specialty and pharmaceuticals businesses," Santosh Varalwar, managing director and chief executive officer of Vivimed said.

The major portion of the receipts will be used to reduce debts thereby saving substantial interest costs going forward, the company said.

The potential transaction was taken on board and forwarded for shareholders approval in a meeting of the board of directors on September 12.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 30 2015 | 12:18 PM IST

Next Story